Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Characterization of Metalloprotease-resistant Reovirus Sigma1 Variants and their Role in Oncolytic Treatment of Breast Cancer

EF 2021-22

Résumé
Oncolytic viruses can be used to target and destroy cancer without harming healthy cells. Clinical trials using an oncolytic reovirus have shown positive results, though the optimization of treatment is required. For example, metalloproteases (MPs), present in the breast cancer tumor microenvironment (TME), have been observed to cleave the ?1 attachment protein of reovirus, thereby reducing tumor clearance. The Shmulevitz lab has previously published that a mutation in the ?1 protein (T249I) can resist MP-mediated cleavage. Aim 1 is to establish the oncolytic activity of MP-resistant reoviruses by comparison to wild-type reovirus in breast cancer models. If the T249I mutation in the ?1 protein protects against MP-mediated cleavage, then an increase in breast cancer clearance should be observed. In Aim 2, the TME of triple-negative breast cancer (TNBC) models will be characterized to determine the repertoire of MP expression. The findings will provide the foundations for the optimization of reovirus clinical treatments. To further provide the means to increase the efficacy of reovirus clinical treatments of breast cancer, reovirus variants will be created with modified ?1 proteins. Aim 3 consists of testing these variants to ensure resistance to MP-mediated cleavage but also show maintained levels of breast cancer infectivity. Additionally, the ?1 protein is immunogenic; therefore, neutralization of reovirus by antibodies will be measured and circumvented by using subsequent doses of ?1 variant reoviruses. Collectively, the findings will provide an understanding of the TME of breast cancers and the barriers to oncolytic virus treatments such as ?1 cleavage while also providing the means to overcome such obstacles.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
467165
Name
Taal Dirk B
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Metalloprotease-resistant Reovirus Sigma1 Variants and their Role in Oncolytic Treatment of Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Metalloprotease; Oncolytic Virus; Reovirus; Reovirus Attachment; Reovirus Sigma 1; Virology
Abstract
Oncolytic viruses can be used to target and destroy cancer without harming healthy cells. Clinical trials using an oncolytic reovirus have shown positive results, though the optimization of treatment is required. For example, metalloproteases (MPs), present in the breast cancer tumor microenvironment (TME), have been observed to cleave the ?1 attachment protein of reovirus, thereby reducing tumor clearance. The Shmulevitz lab has previously published that a mutation in the ?1 protein (T249I) can resist MP-mediated cleavage. Aim 1 is to establish the oncolytic activity of MP-resistant reoviruses by comparison to wild-type reovirus in breast cancer models. If the T249I mutation in the ?1 protein protects against MP-mediated cleavage, then an increase in breast cancer clearance should be observed. In Aim 2, the TME of triple-negative breast cancer (TNBC) models will be characterized to determine the repertoire of MP expression. The findings will provide the foundations for the optimization of reovirus clinical treatments. To further provide the means to increase the efficacy of reovirus clinical treatments of breast cancer, reovirus variants will be created with modified ?1 proteins. Aim 3 consists of testing these variants to ensure resistance to MP-mediated cleavage but also show maintained levels of breast cancer infectivity. Additionally, the ?1 protein is immunogenic; therefore, neutralization of reovirus by antibodies will be measured and circumvented by using subsequent doses of ?1 variant reoviruses. Collectively, the findings will provide an understanding of the TME of breast cancers and the barriers to oncolytic virus treatments such as ?1 cleavage while also providing the means to overcome such obstacles.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Taal, Dirk B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~